Aptevo Therapeutics Announces Promising RAINIER Trial Results

TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off Aptevo Therapeutics ( (APVO) ) just unveiled an announcement. On December 9, 2025, Aptevo Therapeutics announced promising results from its Phase 1b/2 RAINIER trial for mipletamig in combination with azacitidine and venetoclax for newly diagnosed AML patients unfit for intensive chemotherapy. The trial demonstrated high remission rates and a compelling safety profile, with 100% of patients remaining free of cytokine release syndrome. The results underscore mipletamig’s potential as part of a frontline AML regimen, with the study continuing to enroll patients for further evaluation. The most recent analyst rating on (APVO) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Aptevo Therapeutics stock, see the APVO Stock Forecast page. Spark’s Take on APVO Stock According to Spark, TipRanks’ AI Analyst, APVO is a Underperform. Aptevo Therapeutics’ stock score is significantly impacted by its challenging financial performance, marked by declining revenues, high leverage, and negative cash flows. The technical analysis indicates bearish momentum, while the valuation is weakened by persistent losses. However, promising developments in its oncology pipeline offer potential upside if successfully executed. To see Spark’s full report on APVO stock, click here. More about Aptevo Therapeutics Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for cancer treatment. The company utilizes its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies to create therapeutic candidates, including mipletamig for acute myeloid leukemia (AML) and ALG.APV-527 for multiple solid tumors. Average Trading Volume: 5,927,335 Technical Sentiment Signal: Strong Sell Current Market Cap: $22.75M